Join the Oncology Voice Network. Join for Free
Career Satisfaction and Growth: What factors MUST be considered
MSL career satisfaction company culture evaluation aligning core values effective company research MSL roles evolution

Career Satisfaction and Growth: What factors MUST be considered


Share This Article


Summary

In this episode, Tom Caravela is joined by Beth Kupferer to discuss career satisfaction and adaptation in the MSL field. Beth shares insights from her career journey, emphasizing the importance of evaluating leadership, company culture, and aligning with core values. The conversation delves into effective company research and key interview questions. Beth and Tom explore the evolution of MSL roles and team structures post-COVID, highlighting the significance of networking and adapting to KOL preferences. They also discuss the value of live meetings and conferences in the current landscape. The episode concludes with listener appreciation and a request for feedback.

My guest today is Beth Kupferer, National Director, Women’s Health at AbbVie, and we discuss the factors most important for career satisfaction and growth

Beth discusses…

👉 What people need to know when determining next steps for their careers
👉 How people should research companies prior to making the decision to join
👉 What people should be looking for in a company
👉 What MSLs can do to help grow their career
👉 How critical it is for company values to align with personal values
👉 Questions to prepare and ask during an interview

Click for Source
MSL career satisfaction, company culture evaluation, aligning core values, effective company research, MSL roles evolution

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Podcast
MSL Career Options: The transition from Field Medical to Medical Director
Partner Avatar MSL Talk: Tom Caravela, Josh Corriveau

MSL Career Options: The transition from Field Medical to Medical Director

Article
Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials
OVN Avatar Shubham Sharma, J Connor Wells, Wilma M Hopman, Joseph C Del Paggio, Bishal Gyawali, Nazik Hammad, Annette E Hay, Christopher M Booth

Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials

Article
CheckMate-067: Raising the Bar for the Next Decade in Oncology
OVN Avatar Sarah A. Weiss, MD, and Harriet Kluger, MD

CheckMate-067: Raising the Bar for the Next Decade in Oncology

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Explore OVN